Argatroban Reexposure

Across the prospective studies of HIT, 55 patients underwent therapy with argatroban on more than one occasion. The argatroban dosing and duration were similar between these patients (repeat group) and patients upon their first exposure (initial group, n = 754). Event rates in the repeat group were less than with those in the initial group for the composite endpoint (20% vs. 34%), new thrombosis (3.6% vs. 11.1%), and major bleeding (3.6% vs. 6.6%). The patients reexposed to argatroban had no allergic reactions or apparent differences, relative to the initial group, in adverse experiences (Lewis et al., 2000).

0 0

Post a comment